|Bid||2.2000 x 2900|
|Ask||4.0500 x 1400|
|Day's Range||3.0800 - 3.2800|
|52 Week Range||1.8500 - 6.6500|
|Beta (3Y Monthly)||4.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Zosano Pharma Corp (NASDAQ: ZSAN ) shared positive results of Migraine-ACT scores for Qtrypta therapy. The results were presented at the AHS 61st Annual Scientific Meeting. The study assessed the effectiveness ...
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of Migraine-ACT scores for Qtrypta™ therapy used over 6-12 months. The Migraine Assessment of Current Therapy (or Migraine-ACT) questionnaire is a standardized evaluation completed by patients to assess the effectiveness of a patient’s acute treatment of migraine therapy, with the highest achievable score being a four. At their 48-week visit, 89% of participants scored greater than three on the Migraine-ACT questionnaire, while more than 75% scored a four out of four, suggesting optimal acute treatment and no need to change that treatment.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis, senior vice president of operations at Zosano Pharma, will be presenting a keynote speech entitled, “A Novel Intracutaneous Microneedle Delivery System for the Acute Treatment of Migraine” at the Pharmaceutics & Advanced Drug Delivery Systems Conference in Paris on July 5, 2019 at 09:15 am CET. Ms. Lewis’ presentation will review Zosano’s novel and proprietary technology platform, the chemistry, manufacturing, and controls of the company’s lead asset, Qtrypta.
FREMONT, Calif., July 01, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has completed manufacturing of site qualification batches at its commercial manufacturing site for Qtrypta, the company’s investigational treatment for migraines in late stage development. These batches are intended to demonstrate the robustness and reproducibility of the manufacturing process which will be included as part of its planned submission of a New Drug Application (NDA) for Qtrypta in the fourth quarter 2019. "The completion of these site qualification batches forms the basis of our commercial manufacturing process in our NDA and illustrates the scalability of the process as we head toward commercialization activities for Qtrypta at Thermo Fischer, in North Carolina,” said Hayley Lewis, senior vice president, operations at Zosano.
Multiple catalysts, including QtryptaTM NDA submission, anticipated in 2019Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM.
NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Zosano Pharma Corp. (NASDAQ: ZSAN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern ...
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter’s option to purchase additional shares in connection with Zosano’s previously announced public offering of common stock. A total of 5,750,000 shares of common stock have now been sold by Zosano in the offering, resulting in net proceeds to Zosano of approximately $18.4 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Zosano. As previously announced, Zosano intends to use the net proceeds from the offering to fund its ongoing development and preparation for potential commercialization of Qtrypta™ (M207), and for working capital and general corporate purposes.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss results for the first quarter of 2019 and provide an operational update. The Company will announce its financial results for this period in a press release to be issued prior to the call. To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at http://ir.zosanopharma.com/events.cfm.
In December 2018, Zosano Pharma Corporation (NASDAQ:ZSAN) announced its latest earnings update, which showed that losses became smaller relative to the prior year's level as a result of recent tailwi...
In this analysis, researchers reviewed eight published trials designed in accordance with the Guidance for Industry, “Migraine: Developing Drugs for Acute Treatment”, finalized in February 2018, that recommended using co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS) at 2-hours post-treatment. Using the placebo response rates from these various trials, the authors were able to calculate required sample sizes for future trials and compare these calculations to the sample sizes actually used in completed trials.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Zosano. The offering is expected to close on or about April 11, 2019, subject to the satisfaction of customary closing conditions. Cantor Fitzgerald & Co. is the sole book-running manager for the offering. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on March 27, 2019.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. In addition, Zosano intends to grant to the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions.
Zosano Pharma Corporation , a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018, as well as recent business highlights.
FREMONT, Calif., March 11, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief.
FREMONT, Calif., March 07, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and.
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Nearly every day, headlines are popping up surrounding these innovative companies in the healthcare industry as they tackle the prevalent need for qualitative care. Whereas other industries may have different core values and purposes, healthcare companies are tasked with keeping consumers healthy and amid that responsibility, if done correctly, lies the potential for lucrative opportunities. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Zosano Pharma Corporation (ZSAN), Achieve Life Sciences Inc (ACHV), and Aurora Cannabis Inc (ACB) represent four healthcare companies focused on the advancement of the global healthcare industry.
Biotech and healthcare stocks are loved by traders for their big price moves, which usually happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and rejections), can send stocks soaring. Recent examples include Amarin Corp's (AMRN) 3X move in one day, or Zosano Pharma Corporations' (ZSAN) 100% rip on recent study results.
ParcelPal Technology Inc (PTNYF) (PKG), Sequans Communications S.A. (SQNS), Zosano Pharma Corporation (ZSAN), and EnSync Inc (ESNC) represent 4 tech stocks on the rise on Thursday. The Company's on-demand delivery platform has garnered notoriety for its ease of use. ParcelPal Technology Inc (PTNYF) (PKG) announced towards the end of last month that the Company had formed a partnership with MADD Canada to aid in the continuous fight to prevent impaired driving.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Zosano Pharma Corporation (NASDAQ:ZSAN) haveRead More...
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the completion of the second and final goal of the long-term safety study for Qtrypta, in which patients treated migraine attacks over a one year period. The long-term data generated in this trial reinforced the well-tolerated safety profile and strong efficacy results previously reported in the six-month dosing portion of this safety study and in the randomized Phase 2/3 ZOTRIP pivotal study. Throughout the clinical program, over 5,800 migraine attacks have been treated with Qtrypta to date.
In this post-hoc analysis, researchers examined the efficacy of Qtrypta™ in treating subsets of patients whose migraines have traditionally been difficult-to-treat and have been associated with poorer outcomes when treated with oral medications. Migraine characteristics including severe pain, duration of migraine of more than 2 hours, awakening with migraine, and the presence of nausea are established factors that predict a poorer response to traditional migraine treatment.